KYMR Q2 2021 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+463.2% YoY

Gross Profit

$19M100.0% margin

Operating Income

-$25M-133.5% margin

Net Income

-$25M-133.2% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$434M

Total Liabilities

$176M

Stockholders' Equity

$258M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$3M	+463.2%
Gross Profit	$19M	$3M	+463.2%
Operating Income	-$25M	-$14M	-74.3%
Net Income	-$25M	-$14M	-76.3%